4//SEC Filing
Blume-Jensen Peter 4
Accession 0000905148-24-003287
CIK 0001781174other
Filed
Nov 26, 7:00 PM ET
Accepted
Nov 27, 6:04 PM ET
Size
9.5 KB
Accession
0000905148-24-003287
Insider Transaction Report
Form 4
Blume-Jensen Peter
DirectorPresident and CEO
Transactions
- Award
Stock Option (Right to Buy)
2024-03-01+225,226→ 225,226 totalExercise: $5.70Exp: 2034-02-28→ Common Stock (225,226 underlying) - Award
Stock Option (Right to Buy)
2024-03-01+90,090→ 90,090 total(indirect: See Footnote)Exercise: $5.70Exp: 2034-02-28→ Common Stock (90,090 underlying)
Masson Kristina
DirectorEVP - Business Operations
Transactions
- Award
Stock Option (Right to Buy)
2024-03-01+225,226→ 225,226 totalExercise: $5.70Exp: 2034-02-28→ Common Stock (225,226 underlying) - Award
Stock Option (Right to Buy)
2024-03-01+90,090→ 90,090 total(indirect: See Footnote)Exercise: $5.70Exp: 2034-02-28→ Common Stock (90,090 underlying)
Footnotes (3)
- [F1]Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2025, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date.
- [F2]These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein.
- [F3]These securities are held by co-founder and EVP, Dr. Kristina Masson, who is also Dr. Blume-Jensen's spouse. Dr. Blume-Jensen disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Documents
Issuer
Acrivon Therapeutics, Inc.
CIK 0001781174
Entity typeother
Related Parties
1- filerCIK 0001950499
Filing Metadata
- Form type
- 4
- Filed
- Nov 26, 7:00 PM ET
- Accepted
- Nov 27, 6:04 PM ET
- Size
- 9.5 KB